Editorials
Assessment of Enthesitis in Psoriatic Arthritis
P.S. Helliwell .......................... 869
Treatment of Lyme Arthritis  A.C. Steere ................. 871

Rheumatoid Arthritis
Effect of Concomitant DMARD and MTX Administration Route on Biologic Treatment Durability in RA: OBRI Cohort Results  A.N. Lau, J.C. Thorne, M. Movahedi, et al, and the OBRI Investigators .......................... 874
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic DMARD in RA  C. Peterfy, J. DiCarlo, P. Emery, et al. .......................... 887

Spondylitis
Clinical Characteristics of Patients with SpA in Japan in Comparison with Other Regions of the World  M. Kishimoto, K. Yoshida, N. Ichikawa, et al .......................... 896

Psoriatic Arthritis

Systemic Lupus Erythematosus

Systemic Sclerosis

Vasculitis

Myositis
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease  T. Fujisawa, H. Hozumi, H. Yasui, et al .......................... 935

Pediatric Rheumatology


Images in Rheumatology
A Great Masquerader: Chronic Active Epstein-Barr Virus for the Rheumatologist  A. Chhabra, R. Alyazidi, A. Human .......................... 960

OMERACT 2018: International Consensus Conference on Outcome Measures in Rheumatology, Terrigal, Australia, May 2018
Introduction  L. March, B. Richards, M. Gill, et al. .......................... 962

Contents continued on page xii
Workshops and Special Sessions

The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders

Uptake of the OMERACT-OARSI Hip and Knee OA Core Outcome Set: Review of RCT from 1997 to 2017

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee OA

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess PsA-specific Health-related Quality of Life in Clinical Trials
A.M. Orbai, R. Holland, Y.Y. Leung, et al. .......................... 990

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 PsA Workshop Report

Establishing an Updated Core Domain Set for Studies in JIA: A Report from the OMERACT 2018 JIA Workshop
E.M. Morgan, J.E. Munro, J. Horonjeff, et al. ................. 1006

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology

The Third Biennial 2018 OMERACT First-time Participant Program: A Qualitative and Quantitative Study
V.S. Sloan, S. Grosskleg, G. Wells, J.A. Singh ...................... 1036

Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development

The OMERACT Emerging Leaders Program: The Good, the Bad, and the Future
C.A. Flurey, P.S. Tugwell, R.J. Black, et al. .................... 1047

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for RCT
K.M. Andersen, J.T. Cheah, L. March, et al. .................... 1053

Letter

Thirty Years of Followup in 3 Patients with Familial Polyarteritis Nodosa due to Adenosine Deaminase 2 Deficiency
J. Liebowitz, D.B. Hellmann, O. Schnappauf ....................... 1059

Meetings ................................................................. vi